22.626 articles found

Method of using (2-imidazolin-2-ylamino) quinoxalines in the treatment of dementia and parkinsons

DONELLO JOHN E, GIL DANIEL W, TATTON WILLIAM G, WHEELER LARRY A.

· 2010-02-26

TREATMENT OF DYSKINESIA RELATED DISORDERS

WIKSTROEM HAAKAN, JOERGENSEN MORTEN, MOERK NIELS, LARSEN JENNIFER, TORUP LARS, BANG-ANDERSEN BENNY.

· 2010-02-26

Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease.

Wang YH, Samoylenko V, Tekwani BL, Khan IA, Miller LS, Chaurasiya ND, Rahman MM, Tripathi LM, Khan SI, Joshi VC, Wigger FT, Muhammad I.

J Ethnopharmacol · 2010-02-26

DOI: 10.1016/j.jep.2010.02.013PMID: 20219660

P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases.

Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, Kitani H, Hashimoto M.

Arch Immunol Ther Exp (Warsz) · 2010-02-09

DOI: 10.1007/s00005-010-0069-yPMID: 20143170

N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES

GRIFFIOEN GERARD, ROJAS DE LA PARRA VERONICA, LAUWERS ANNICK.

· 2010-02-05

Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.

Narayana S, Fox PT, Zhang W, Franklin C, Robin DA, Vogel D, Ramig LO.

Hum Brain Mapp · 2010-02-01

DOI: 10.1002/hbm.20859PMID: 19639554

Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.

Tapias V, Cannon JR, Greenamyre JT.

J Neurosci Res · 2010-02-01

DOI: 10.1002/jnr.22201PMID: 19681169

Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.

Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Ryu JS, Kim GS, Lee MC, Koh JM, Chung SJ.

Mov Disord · 2010-02-01

DOI: 10.1002/mds.22866PMID: 19938151

Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems.

Hwang DY, Kim DS, Kim DW.

J Cell Biochem · 2010-02-01

DOI: 10.1002/jcb.22411PMID: 20014069

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Kulisevsky J, Pagonabarraga J.

Drug Saf · 2010-02-01

DOI: 10.2165/11319860-000000000-00000PMID: 20082541

Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P.

CNS Drugs · 2010-02-01

DOI: 10.2165/11310940-000000000-00000PMID: 20088619

Levodopa delivery systems: advancements in delivery of the gold standard.

Ngwuluka N, Pillay V, Du Toit LC, Ndesendo V, Choonara Y, Modi G, Naidoo D.

Expert Opin Drug Deliv · 2010-02-01

DOI: 10.1517/17425240903483166PMID: 20095943